Biovie Inc (BIVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biovie Inc (BIVI) has a cash flow conversion efficiency ratio of -0.477x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.44 Million) by net assets ($15.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biovie Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Biovie Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Biovie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biovie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovie Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PATERSON RESOURCES LTD
F:U40
|
N/A |
|
Perpetual Resources Ltd
AU:PEC
|
-0.164x |
|
Zacatecas Silver Corp
V:ZAC
|
-0.018x |
|
Steel City Securities Limited
NSE:STEELCITY
|
0.025x |
|
Inocycle Technology Tbk PT
JK:INOV
|
0.029x |
|
Taoping Inc
NASDAQ:TAOP
|
-0.038x |
|
Bitcoin Well Inc
V:BTCW
|
0.195x |
|
Redcastle Resources Ltd
AU:RC1
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Biovie Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Biovie Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Biovie Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $19.01 Million | $-19.03 Million | -1.001x | +44.47% |
| 2024-06-30 | $15.51 Million | $-27.95 Million | -1.802x | +31.32% |
| 2023-06-30 | $15.34 Million | $-40.25 Million | -2.624x | +49.28% |
| 2022-06-30 | $3.67 Million | $-18.99 Million | -5.173x | -149.94% |
| 2021-06-30 | $5.05 Million | $-10.45 Million | -2.070x | -2832.88% |
| 2020-06-30 | $-21.50 Million | $-1.63 Million | 0.076x | +106.45% |
| 2019-06-30 | $2.13 Million | $-2.50 Million | -1.174x | +78.99% |
| 2018-06-30 | $111.20K | $-621.34K | -5.588x | -936.97% |
| 2017-06-30 | $1.16 Million | $-623.62K | -0.539x | -530.93% |
| 2016-06-30 | $1.92 Million | $-163.63K | -0.085x | -107.07% |
| 2015-06-30 | $-54.12K | $-65.38K | 1.208x | +219.80% |
| 2014-06-30 | $171.39K | $-172.83K | -1.008x | -4828.56% |
| 2013-06-30 | $490.70K | $-10.04K | -0.020x | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more